AU2009277811B2 - MELK epitope peptides and vaccines containing the same - Google Patents

MELK epitope peptides and vaccines containing the same Download PDF

Info

Publication number
AU2009277811B2
AU2009277811B2 AU2009277811A AU2009277811A AU2009277811B2 AU 2009277811 B2 AU2009277811 B2 AU 2009277811B2 AU 2009277811 A AU2009277811 A AU 2009277811A AU 2009277811 A AU2009277811 A AU 2009277811A AU 2009277811 B2 AU2009277811 B2 AU 2009277811B2
Authority
AU
Australia
Prior art keywords
peptide
cancer
set forth
peptides
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009277811A
Other languages
English (en)
Other versions
AU2009277811A1 (en
AU2009277811A8 (en
Inventor
Ryuji Ohsawa
Takuya Tsunoda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of AU2009277811A1 publication Critical patent/AU2009277811A1/en
Publication of AU2009277811A8 publication Critical patent/AU2009277811A8/en
Application granted granted Critical
Publication of AU2009277811B2 publication Critical patent/AU2009277811B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009277811A 2008-08-01 2009-07-30 MELK epitope peptides and vaccines containing the same Ceased AU2009277811B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8566308P 2008-08-01 2008-08-01
US61/085,663 2008-08-01
PCT/JP2009/003630 WO2010013485A1 (en) 2008-08-01 2009-07-30 Melk epitope peptides and vaccines containing the same

Publications (3)

Publication Number Publication Date
AU2009277811A1 AU2009277811A1 (en) 2010-02-04
AU2009277811A8 AU2009277811A8 (en) 2011-03-03
AU2009277811B2 true AU2009277811B2 (en) 2015-08-20

Family

ID=41610195

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009277811A Ceased AU2009277811B2 (en) 2008-08-01 2009-07-30 MELK epitope peptides and vaccines containing the same

Country Status (15)

Country Link
US (3) US8674069B2 (https=)
EP (1) EP2321411B1 (https=)
JP (1) JP5816918B2 (https=)
KR (1) KR101705514B1 (https=)
CN (1) CN102171340B (https=)
AU (1) AU2009277811B2 (https=)
BR (1) BRPI0916940A2 (https=)
CA (1) CA2732721A1 (https=)
DK (1) DK2321411T3 (https=)
ES (1) ES2572367T3 (https=)
IL (2) IL210861A (https=)
MX (1) MX2011001194A (https=)
SG (1) SG193161A1 (https=)
TW (1) TWI466680B (https=)
WO (1) WO2010013485A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466680B (zh) 2008-08-01 2015-01-01 Oncotherapy Science Inc Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗
TWI485245B (zh) * 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
SG11201405578TA (en) 2012-03-09 2014-11-27 Oncotherapy Science Inc Pharmaceutical composition containing peptide
PT106590B (pt) 2012-10-22 2015-01-20 Secil S A Companhia Geral De Cal E Cimento S A Mistura cimentícia branca ou colorida para fabrico de betão, argamassa e pastas interactivas, com propriedades fotoluminescentes
CN106117337B (zh) * 2016-06-24 2020-02-11 安徽未名细胞治疗有限公司 一种特异性肿瘤抗原sf的ctl识别表位肽及其应用
KR102579047B1 (ko) 2016-08-31 2023-09-14 온코세라피 사이언스 가부시키가이샤 MELK에 대한 단클론 항체(monoclonal antibody) 및 그 사용
KR102614437B1 (ko) * 2021-02-03 2023-12-14 충북대학교 산학협력단 중년 남성 특이적 비만 또는 대사질환의 치료제로서 ｍｐｋ３８／ｍｅｌｋ의 신규 용도
CN121064280A (zh) * 2024-06-04 2025-12-05 复旦大学附属中山医院 一种抗肝癌hla-a*02型疫苗及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005073374A1 (ja) * 2004-01-29 2005-08-11 Dainippon Sumitomo Pharma Co., Ltd. 新規腫瘍抗原蛋白質及びその利用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100209784B1 (ko) 1996-10-08 1999-07-15 박원훈 인간 단백질 변이인산화효소 유전자(hpk 38), 그의 염기 서열, 효소 단백질 및 그의 아미노산 서열
US6229001B1 (en) * 1997-01-03 2001-05-08 Southern Research Institute Mycobacterium fol a gene that encodes for the enzyme dihydrofolate reductase
US6605709B1 (en) * 1999-04-09 2003-08-12 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics
ES2299493T3 (es) * 2000-05-31 2008-06-01 Novartis Vaccines And Diagnostics, Inc. Composiciones y metodos para tratar la enfermedad neoplasica usando sensibilizadores a la radiacion y a la quimioterapia.
US6833447B1 (en) * 2000-07-10 2004-12-21 Monsanto Technology, Llc Myxococcus xanthus genome sequences and uses thereof
US20020156263A1 (en) * 2000-10-05 2002-10-24 Huei-Mei Chen Genes expressed in breast cancer
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
US20030157082A1 (en) 2002-01-31 2003-08-21 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules
US7547534B2 (en) * 2002-06-14 2009-06-16 Verenium Corporation Methods for making a composition to treat a wood, a pulp or a paper
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
WO2004070062A2 (en) 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
ES2609234T3 (es) 2003-06-24 2017-04-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
WO2005016279A2 (en) 2003-08-14 2005-02-24 Exelixis, Inc. Melks as modifiers of the rac pathway and methods of use
DE602005025231D1 (de) 2004-08-10 2011-01-20 Oncotherapy Science Inc Gene und polypeptide in verbindung mit brustkrebserkrankungen
US7915036B2 (en) * 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
EP1856278A2 (en) * 2005-02-10 2007-11-21 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
US20090075832A1 (en) * 2005-02-24 2009-03-19 Cemines, Inc Compositions and Methods for Classifying Biological Samples
CN101283106A (zh) 2005-07-27 2008-10-08 肿瘤疗法科学股份有限公司 小细胞肺癌的诊断方法
CN101287831B (zh) * 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
WO2008023841A1 (en) 2006-08-25 2008-02-28 Oncotherapy Science, Inc. Breast cancer-associated gene, melk, and its interactions with bcl-g
TWI466680B (zh) 2008-08-01 2015-01-01 Oncotherapy Science Inc Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005073374A1 (ja) * 2004-01-29 2005-08-11 Dainippon Sumitomo Pharma Co., Ltd. 新規腫瘍抗原蛋白質及びその利用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIHL, F., et al., The Journal of Immunology, 2006, vol. 176, pages 4094-4101 *

Also Published As

Publication number Publication date
BRPI0916940A2 (pt) 2015-11-24
TWI466680B (zh) 2015-01-01
CN102171340A (zh) 2011-08-31
IL210861A0 (en) 2011-04-28
US9193765B2 (en) 2015-11-24
IL210861A (en) 2015-02-26
DK2321411T3 (en) 2016-06-06
CA2732721A1 (en) 2010-02-04
EP2321411B1 (en) 2016-03-30
IL232461A0 (en) 2014-06-30
AU2009277811A1 (en) 2010-02-04
WO2010013485A1 (en) 2010-02-04
CN102171340B (zh) 2016-12-21
US9675680B2 (en) 2017-06-13
SG193161A1 (en) 2013-09-30
US20110212115A1 (en) 2011-09-01
US20140141028A1 (en) 2014-05-22
JP2011529683A (ja) 2011-12-15
KR20110045018A (ko) 2011-05-03
JP5816918B2 (ja) 2015-11-18
ES2572367T3 (es) 2016-05-31
US20160101171A1 (en) 2016-04-14
KR101705514B1 (ko) 2017-02-10
US8674069B2 (en) 2014-03-18
TW201006486A (en) 2010-02-16
HK1156341A1 (zh) 2012-06-08
EP2321411A1 (en) 2011-05-18
AU2009277811A8 (en) 2011-03-03
EP2321411A4 (en) 2012-12-05
MX2011001194A (es) 2011-03-15

Similar Documents

Publication Publication Date Title
US20110280898A1 (en) Inhbb epitope peptides and vaccines containing the same
US8367799B2 (en) TEM8 peptides and vaccines comprising the same
US10711047B2 (en) CDCA1 epitope peptides and vaccines containing the same
US9675680B2 (en) MELK epitope peptides and vaccines containing the same
WO2010021112A1 (en) Hig2 and urlc10 epitope peptide and vaccines containing the same
AU2009258775B2 (en) MYBL2 epitope peptides and vaccines containing the same
US20110200626A1 (en) Iqgap3 epitope peptides and vaccines containing the same
HK1156341B (en) Melk epitope peptides and vaccines containing the same
HK1155757A (en) Cdca1 epitope peptides and vaccines containing the same
HK1155757B (en) Cdca1 epitope peptides and vaccines containing the same

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 25, NO 7, PAGE(S) 794 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ONCOTHERAPY SCIENCE, INC., APPLICATION NO. 2009277811, UNDER INID (54) CORRECT THE TITLE TO MELK EPITOPE PEPTIDES AND VACCINES CONTAINING THE SAME

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired